Santaris Pharma has appointed Arthur Levin, its chief development officer, as president of its new California-based subsidiary.
Levin previously served as vice president of drug development at Isis Pharmaceuticals. He holds a PhD in toxicology from the University of Rochester School of Medicine and Dentistry.